



*“Stay Ahead of the Game:
Transformation in Clinical Trials
in the Age of Artificial Intelligence.”*

ANNUAL CLINICAL TRIALS SYMPOSIUM

November 8th, 2024

This material is the exclusive property of the Avantyo Institute of Clinical Research.
Any reproduction or distribution of this content is strictly prohibited without prior authorization and may result in legal action!

ROMANIA AND EUROPE'S STRATEGIC ROLE IN SHAPING GLOBAL CLINICAL TRIALS: NAVIGATING REGULATIONS AND OPPORTUNITIES

DR. CLAUDIA HESSELMANN, PHD
FOUNDER & CEO



GERMAN COMPANY

15 YEARS

14 CLINICS

8 COUNTRIES

600 EMPLOYEES



EXPLORATORY PATIENT TRIALS WITH NOVEL TARGETS

GERMANY. USA. ROMANIA. BULGARIA. UKRAINE. MOLDOVA. GEORGIA. MOROCCO

GLOBAL CHALLENGES:

POLITICAL TURBULENCE

ECONOMIC VOLATILITY

STAFF SHORTAGES

AI IMPACT


INDUSTRY TRENDS:

ADVANCED THERAPEUTICS

MORE COMPLEX STUDIES

INCREASING EXPENSE

GREATER BUREAUCRACY



**BENEFITS
CLINICAL TRIALS**

REGULATORY FRAME

RESEARCH INFRASTRUCTURE

HEALTHCARE INFRASTRUCTURE

MEDICAL EXPERTISE

A black and white composite image. In the foreground, a horse is harnessed to a wooden trailer. On the trailer sits a red Formula 1 race car. A man wearing a hat and a plaid shirt is sitting on the trailer, holding the reins of the horse. The scene is set on a paved road that stretches into the distance under a cloudy sky. The overall image is in grayscale, except for the red of the Formula 1 car.

**SPEED IS OF ESSENCE
IN DRUG DEVELOPMENT**


ONGOING CLINICAL TRIALS WORLD-WIDE

COUNTRY	TOTAL NO. OF STUDIES
UNITED STATES	26,256
CHINA	12,547
CANADA	4,376
UNITED KINGDOM	3,472
SPAIN	2,791
FRANCE	2,717
GERMANY	2,264
ITALY	2,082
SOUTH KOREA	2,136
BELGIUM	1,384
ROMANIA	430


CONDITION	2020 FUNDING
CANCER	\$7.035 BILLION
HIV/AIDS	\$3.076 BILLION
ALZHEIMER'S DISEASE	\$2.683 BILLION
CARDIOVASCULAR	\$2.536 BILLION
CORONAVIRUSES	\$2.355 BILLION
HEART DISEASE	\$1.606 BILLION
DIABETES	\$1.156 BILLION
OBESITY	\$1.145 BILLION
EYE DISEASE AND DISORDERS OF VISION	\$1.012 BILLION
CEREBROVASCULAR	\$888 MILLION

**NEW APPROACHES TO FIGHT DISEASES
PROVIDING IMPORTANT INNOVATIVE
TREATMENT OPTIONS FOR PHYSICIANS
AND HEALTH BENEFITS FOR PATIENTS.**


FIRST-IN-CLASS DRUGS US FILING



ORIGIN OF NEW DRUG PATENTS BY COUNTRY



PATENT FILLING IN GLOBAL PHARMA IQ 2024



EUROPE

COUNTRY	OVERALL TIMELINE (DAYS)
---------	-------------------------

EU	60-106
SERBIA	60
UKRAINE	35
GEORGIA	30
MOLDOVA	10

GLOBAL

US	30-45
CANADA	30
UK	30
AUSTRALIA	15-30
NEW ZEALAND	15-30

COUNTRY APPROVAL TIMELINES

MONO-NATIONAL APPROVAL TIMELINES:


COUNTRY	OVERALL TIMELINE (DAYS)
BULGARIA	30
BELGIUM	30
GERMANY	30

**60,000 FEWER
CLINICAL TRIAL PLACES
FOR EUROPEANS**

DESPITE GLOBAL CLINICAL TRIALS INCREASING BY 38% OVER THE PAST DECADE, THE EUROPEAN ECONOMIC AREA'S (EEA) GLOBAL SHARE OF TRIALS HAS HALVED OVER THE SAME PERIOD.

A NEW REPORT BY IQVIA FOR EFPIA AND VACCINES EUROPE, SHOWS THAT THE EEA'S SHARE OF COMMERCIAL TRIALS — THOSE SPONSORED BY A PHARMACEUTICAL COMPANY — HAS REDUCED FROM 22% IN 2013, TO 18% IN 2018 TO 12% IN 2023.

APPROVED CLINICAL TRIALS IN ROMANIA





THANK YOU!

CLAUDIA.HESSELMANN@ARENSIA-EM.COM

WWW.ARENSIA-EM.COM